for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Compugen Ltd. (USA)

CGEN.OQ

Latest Trade

17.55USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.41

 - 

18.02

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.55
Open
--
Volume
--
3M AVG Volume
30.14
Today's High
--
Today's Low
--
52 Week High
18.02
52 Week Low
3.41
Shares Out (MIL)
82.69
Market Cap (MIL)
1,346.26
Forward P/E
-38.19
Dividend (Yield %)
--

Next Event

Compugen Ltd Annual Shareholders Meeting

Latest Developments

More

Compugen Reports Q2 Loss Per Share $0.08

Compugen Reports FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701

Compugen Reports Q1 Loss Per Share $0.10

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Compugen Ltd. (USA)

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Industry

Biotechnology & Drugs

Contact Info

Azrieli Center, 26 Harokmim St. Bldg D

5885849

Israel

+972.3.7658585

http://cgen.com/

Executive Leadership

Paul Jai Sekhri

Chairman of the Board

Anat Cohen-Dayag

President, Chief Executive Officer, Director

Ari Krashin

Chief Financial Officer

Zurit Levine

Vice President - Research and Discovery

John Hunter

Vice President - Antibody Research & Development

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.720

2018

-0.410

2019

-0.430

2020(E)

-0.373
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
8.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-29.40
Return on Equity (TTM)
-27.11

Latest News

Latest News

Bristol-Myers to invest in Compugen, collaborate in clinical trials

Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumors.

BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018

* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Compugen Announces Exclusive License Agreement With Medimmune

* CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text (https://bit.ly/2GsywkV) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Compugen, AstraZeneca unit in cancer drug development deal

Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million.

BRIEF-Compugen Reports Q4 Loss Per Share Of $0.18

* COMPUGEN - AS OF DEC 31, 2017, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $30.4 MILLION, COMPARED WITH $61.5 MILLION LAST YEAR Source text for Eikon: Further company coverage:

BRIEF-COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19

* AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage:

BRIEF-Compugen to initiate manufacturing of COM902

* Compugen Ltd - advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019

BRIEF-Compugen appoints Paul Sekhri as new board chairman

* Compugen welcomes paul sekhri as its new chairman of the board

BRIEF-Compugen Q2 loss per share $0.18

* Compugen ltd - names paul sekhri as chairman of board effective october 2, 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up